PrECOG
@precogonc.bsky.social
Innovative cancer research studies developed through industry partnerships and networks. Supporting ECOG-ACRIN's efforts to advance cancer care
Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
November 11, 2025 at 9:07 PM
Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Reposted by PrECOG
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma | OncLive
Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.
bit.ly
November 6, 2025 at 3:29 PM
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
November 5, 2025 at 2:08 PM
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
October 29, 2025 at 2:00 PM
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
October 15, 2025 at 4:37 PM
Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to the following institutions for enrolling their first patients in #RealWorldData #PatientRegistry PrE1702: Sibley Memorial Hospital, Good Samaritan University Hospital, and Northwestern University! More info here: bit.ly/pre1702-study #LCSM #RWD #RWE
ClinicalTrials.gov
bit.ly
October 7, 2025 at 4:06 PM
Kudos to the following institutions for enrolling their first patients in #RealWorldData #PatientRegistry PrE1702: Sibley Memorial Hospital, Good Samaritan University Hospital, and Northwestern University! More info here: bit.ly/pre1702-study #LCSM #RWD #RWE
Kudos to The Valley Hospital (Luckow Pavilion) for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
September 25, 2025 at 6:28 PM
Kudos to The Valley Hospital (Luckow Pavilion) for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to Aurora Saint Luke’s Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
September 10, 2025 at 2:17 PM
Kudos to Aurora Saint Luke’s Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to John H. Stroger, Jr. Hospital of Cook County for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 29, 2025 at 4:12 PM
Kudos to John H. Stroger, Jr. Hospital of Cook County for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
University of Wisconsin Carbone Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 29, 2025 at 4:05 PM
University of Wisconsin Carbone Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Sibley Memorial Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 20, 2025 at 2:25 PM
Sibley Memorial Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to The University of Alabama at Birmingham for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 19, 2025 at 6:09 PM
Kudos to The University of Alabama at Birmingham for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue
Reposted by PrECOG
ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
August 5, 2025 at 3:10 PM
ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
July 28, 2025 at 3:30 PM
Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Kudos to The Cancer Institute at Saint Francis Hospital for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
July 8, 2025 at 4:17 PM
Kudos to The Cancer Institute at Saint Francis Hospital for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Good Samaritan University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
July 8, 2025 at 4:14 PM
Good Samaritan University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Kudos to SUNY Upstate Medical University for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
June 24, 2025 at 2:03 PM
Kudos to SUNY Upstate Medical University for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue
Kudos to Allegheny General Hospital for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
June 13, 2025 at 7:33 PM
Kudos to Allegheny General Hospital for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
The Cancer Institute at St. Francis Hospital & UNC Pardee Cancer Center are now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
June 13, 2025 at 7:30 PM
The Cancer Institute at St. Francis Hospital & UNC Pardee Cancer Center are now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Gundersen Lutheranis now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
June 11, 2025 at 7:21 PM
Gundersen Lutheranis now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Montefiore Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
June 3, 2025 at 1:25 PM
Montefiore Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Carle Cancer Institute is enrolling pts in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
May 29, 2025 at 7:27 PM
Carle Cancer Institute is enrolling pts in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
O'Neal Comprehensive Cancer Center at UAB is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
May 20, 2025 at 1:53 PM
O'Neal Comprehensive Cancer Center at UAB is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Great work to @penncancer.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
May 9, 2025 at 1:57 PM
Great work to @penncancer.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Great work to Mercyhealth Hospital and Cancer Center Janesville for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
April 28, 2025 at 1:49 PM
Great work to Mercyhealth Hospital and Cancer Center Janesville for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue